Biophytis S.A. (ALBPS) - Total Assets
Based on the latest financial reports, Biophytis S.A. (ALBPS) holds total assets worth €6.62 Million EUR (≈ $7.74 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biophytis S.A. - Total Assets Trend (2012–2024)
This chart illustrates how Biophytis S.A.'s total assets have evolved over time, based on quarterly financial data. Also see Biophytis S.A. market capitalisation for the company's overall valuation and market capitalisation.
Biophytis S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Biophytis S.A.'s total assets of €6.62 Million consist of 56.9% current assets and 43.1% non-current assets. Review ALBPS total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 1.1% |
| Accounts Receivable | €3.47 Million | 50.3% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €231.00K | 3.4% |
| Intangible Assets | €2.61 Million | 37.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Biophytis S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Biophytis S.A. for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biophytis S.A.'s current assets represent 56.9% of total assets in 2024, a decrease from 95.4% in 2012.
- Cash Position: Cash and equivalents constituted 1.1% of total assets in 2024, down from 51.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 50.3% of total assets.
Biophytis S.A. Competitors by Total Assets
Key competitors of Biophytis S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Biophytis S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.35 | 0.41 | 0.81 |
| Quick Ratio | 0.35 | 0.41 | 0.81 |
| Cash Ratio | 0.08 | 0.13 | 0.18 |
| Working Capital | €-7.14 Million | €-8.35 Million | €-3.66 Million |
Biophytis S.A. - Advanced Valuation Insights
This section examines the relationship between Biophytis S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.25 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | -42.3% |
| Total Assets | €6.90 Million |
| Market Capitalization | $2.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biophytis S.A.'s assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biophytis S.A.'s assets decreased by 42.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biophytis S.A. (2012–2024)
The table below shows the annual total assets of Biophytis S.A. from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €6.90 Million ≈ $8.07 Million |
-42.29% |
| 2023-12-31 | €11.96 Million ≈ $13.98 Million |
-45.60% |
| 2022-12-31 | €21.99 Million ≈ $25.71 Million |
-39.37% |
| 2021-12-31 | €36.26 Million ≈ $42.39 Million |
+33.27% |
| 2020-12-31 | €27.21 Million ≈ $31.81 Million |
+53.97% |
| 2019-12-31 | €17.67 Million ≈ $20.66 Million |
-19.17% |
| 2018-12-31 | €21.86 Million ≈ $25.56 Million |
-15.74% |
| 2017-12-31 | €25.95 Million ≈ $30.33 Million |
+209.15% |
| 2016-12-31 | €8.39 Million ≈ $9.81 Million |
-37.91% |
| 2015-12-31 | €13.52 Million ≈ $15.80 Million |
+3393.95% |
| 2014-12-31 | €386.86K ≈ $452.28K |
-38.38% |
| 2013-12-31 | €627.76K ≈ $733.92K |
-48.11% |
| 2012-12-31 | €1.21 Million ≈ $1.41 Million |
-- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more